Please provide your email address to receive an email when new articles are posted on . PASI and static Physician Global Assessment scores significantly improved in pediatric patients with psoriasis ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- ...

Please provide your email address to receive an email when new articles are posted on . Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis.

The sNDA was supported by data from a 4 week MUSE study and a long-term open-label study in children aged 2 to 5 years.

Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to ...

The US FDA has approved guselkumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in children aged 6 years or older who weigh at least 40 kg, according ...

Guttate psoriasis causes small, round bumps. It's typically triggered by a Streptococcus (strep) bacteria infection. Guttate psoriasis most commonly affects children and adolescents. This condition is ...

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful ...

WESTLAKE VILLAGE, Calif. - The U.S. Food and Drug Administration has accepted Arcutis Biotherapeutics’ (NASDAQ:ARQT) supplemental New Drug Application for ZORYVE cream 0.3% to treat plaque psoriasis ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in ...

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...